TY - JOUR T1 - Advances in pulmonary and pleural malignant disorders JF - Clinical Medicine JO - Clin Med SP - 234 LP - 236 DO - 10.7861/clinmedicine.19-3-234 VL - 19 IS - 3 AU - Jack A Kastelik AU - Angshu Bhowmik AU - John Park Y1 - 2019/05/01 UR - http://www.rcpjournals.org/content/19/3/234.abstract N2 - Lung and pleural malignancies remain common in the UK with poor survival rates due, at least in part, to late stage diagnosis. Diagnostic pathways aim to reduce the time taken for patients to reach a diagnosis and treatment, with the use of positron emission tomography and endobronchial ultrasound to provide staging information alongside diagnostics. Advances in molecular phenotyping of tumours and the development of treatments to target these have provided new therapeutic options which can be individualised to patients. In the UK, screening for lung cancer remains in its infancy, but provides a promising possibility for capturing curative disease. We provide an overview of the diagnostic process, therapeutic options and potential future screening programmes in pleural and pulmonary malignancies. ER -